22:50 , Nov 17, 2016 |  BC Week In Review  |  Company News

Biodel, Albireo deal

Albireo and Biodel merged to form Albireo Pharma Inc. (NASDAQ:ALBO, Boston, Mass.). The company plans to start a pivotal trial of lead compound A4250 next year to treat progressive familial intrahepatic cholestasis (PFIC). A4250 is...
07:00 , Oct 3, 2016 |  BC Extra  |  Clinical News

Albireo's elobixibat meets in Japanese Phase III study

Albireo AB (Gothenburg, Sweden) said elobixibat (AJG533/ A3309 ) met the primary endpoint in a Japanese Phase III study to treat chronic constipation. Compared with placebo, elobixibat significantly improved the number of weekly spontaneous bowel...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

BioD, Derma Sciences deal

Derma acquired regenerative medicine company BioD for $13.8 million in cash, $7.5 million in stock, up to $30 million in regulatory milestones and up to $26.5 million in incremental net sales milestones. In a concurrent...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Company News

Biodel endocrine/metabolic news

In January, Biodel reduced headcount by 15 non-executive employees to preserve cash. The company expects to reduce average operating cash burn to about $1.1 million from $4.5 million per quarter. Biodel declined to disclose how...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

BIOD-531: Phase IIa started

Biodel began the Phase IIa Study 3-157 to compare BIOD-531 alone or in combination with Victoza liraglutide vs. Humalog insulin lispro plus Lantus insulin glargine in 14 Type II diabetics. Patients will receive 4 treatments:...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Biodel endocrine/metabolic news

Biodel will reduce headcount by 10 (30%) to about 23 and restructure research and quality-related activities to focus on later-stage clinical development programs. The company expects the restructuring to save about $2 million annually. In...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

BIOD-531: Phase IIb started

Biodel began the open-label, U.S. Phase IIb Study 3-250 to compare twice daily subcutaneous BIOD-531 vs. Humalog Mix 75/25 insulin lispro protamine/insulin lispro twice daily for 18 weeks in about 130 patients. Biodel Inc. (NASDAQ:BIOD),...